JP2013523175A - 高力価、高純度のウイルスストックの作製方法及びその使用方法 - Google Patents
高力価、高純度のウイルスストックの作製方法及びその使用方法 Download PDFInfo
- Publication number
- JP2013523175A JP2013523175A JP2013504963A JP2013504963A JP2013523175A JP 2013523175 A JP2013523175 A JP 2013523175A JP 2013504963 A JP2013504963 A JP 2013504963A JP 2013504963 A JP2013504963 A JP 2013504963A JP 2013523175 A JP2013523175 A JP 2013523175A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- tcid
- sample
- less
- high purity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 502
- 238000000034 method Methods 0.000 title claims abstract description 199
- 238000004519 manufacturing process Methods 0.000 title abstract description 39
- 230000008569 process Effects 0.000 claims abstract description 62
- 238000012360 testing method Methods 0.000 claims abstract description 61
- 239000012535 impurity Substances 0.000 claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 90
- 102000004169 proteins and genes Human genes 0.000 claims description 90
- 239000012528 membrane Substances 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 41
- 238000005341 cation exchange Methods 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 35
- 239000000872 buffer Substances 0.000 claims description 29
- 239000011550 stock solution Substances 0.000 claims description 28
- 239000002609 medium Substances 0.000 claims description 25
- 238000005199 ultracentrifugation Methods 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 19
- 238000004113 cell culture Methods 0.000 claims description 15
- 238000001556 precipitation Methods 0.000 claims description 15
- 238000000108 ultra-filtration Methods 0.000 claims description 14
- 238000011062 flow through chromatography Methods 0.000 claims description 13
- 230000002779 inactivation Effects 0.000 claims description 11
- 241000125945 Protoparvovirus Species 0.000 claims description 9
- 238000011156 evaluation Methods 0.000 claims description 8
- 230000001376 precipitating effect Effects 0.000 claims description 8
- 241000713893 Xenotropic murine leukemia virus Species 0.000 claims description 7
- 239000012501 chromatography medium Substances 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 238000009295 crossflow filtration Methods 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 241001515965 unidentified phage Species 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 5
- 230000007717 exclusion Effects 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 238000012421 spiking Methods 0.000 claims description 5
- 238000004220 aggregation Methods 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 241000714177 Murine leukemia virus Species 0.000 claims 1
- 239000012530 fluid Substances 0.000 abstract description 8
- 238000012368 scale-down model Methods 0.000 abstract description 6
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 238000004513 sizing Methods 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 46
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 21
- 239000006166 lysate Substances 0.000 description 20
- 238000005498 polishing Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 239000012091 fetal bovine serum Substances 0.000 description 14
- 239000008188 pellet Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 239000012465 retentate Substances 0.000 description 12
- 229960000074 biopharmaceutical Drugs 0.000 description 11
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 9
- 238000010200 validation analysis Methods 0.000 description 9
- 239000006143 cell culture medium Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 7
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 208000002109 Argyria Diseases 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 4
- 239000010836 blood and blood product Substances 0.000 description 4
- 229940125691 blood product Drugs 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 241000702321 Microvirus Species 0.000 description 3
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
- 241000702619 Porcine parvovirus Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 244000309711 non-enveloped viruses Species 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000010977 unit operation Methods 0.000 description 3
- 239000013621 viresolve pro solution Substances 0.000 description 3
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 241000709701 Human poliovirus 1 Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000702623 Minute virus of mice Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000012574 advanced DMEM Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000011018 current good manufacturing practice Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 241000700635 Orf virus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000709749 Pseudomonas phage PP7 Species 0.000 description 1
- 241000702217 Pseudomonas virus phi6 Species 0.000 description 1
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011028 process validation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013017 sartobind Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000012607 strong cation exchange resin Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14351—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32422010P | 2010-04-14 | 2010-04-14 | |
| US61/324,220 | 2010-04-14 | ||
| PCT/US2011/031747 WO2011130119A2 (en) | 2010-04-14 | 2011-04-08 | Methods of producing high titer, high purity virus stocks and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015081173A Division JP6284500B2 (ja) | 2010-04-14 | 2015-04-10 | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2013523175A true JP2013523175A (ja) | 2013-06-17 |
Family
ID=44148425
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013504963A Pending JP2013523175A (ja) | 2010-04-14 | 2011-04-08 | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
| JP2015081173A Expired - Fee Related JP6284500B2 (ja) | 2010-04-14 | 2015-04-10 | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
| JP2017134066A Expired - Fee Related JP6522054B2 (ja) | 2010-04-14 | 2017-07-07 | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015081173A Expired - Fee Related JP6284500B2 (ja) | 2010-04-14 | 2015-04-10 | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
| JP2017134066A Expired - Fee Related JP6522054B2 (ja) | 2010-04-14 | 2017-07-07 | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9644187B2 (https=) |
| EP (1) | EP2377927B1 (https=) |
| JP (3) | JP2013523175A (https=) |
| KR (1) | KR101549296B1 (https=) |
| CN (1) | CN102985536B (https=) |
| BR (1) | BR112012026095A2 (https=) |
| ES (1) | ES2736166T3 (https=) |
| SG (1) | SG184833A1 (https=) |
| WO (1) | WO2011130119A2 (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021114907A (ja) * | 2020-01-22 | 2021-08-10 | 旭化成メディカル株式会社 | パルボウイルスの生産方法 |
| WO2021172573A1 (ja) * | 2020-02-28 | 2021-09-02 | 旭化成メディカル株式会社 | ウイルスクリアランス性能の評価方法 |
| WO2022270105A1 (ja) * | 2021-06-24 | 2022-12-29 | 株式会社島津製作所 | ウイルス試料の濃縮方法 |
| JP2023544512A (ja) * | 2020-09-21 | 2023-10-24 | バイエル・ヘルスケア・エルエルシー | 病原体クリアランスシステムおよび方法 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
| DE102010046817A1 (de) * | 2010-09-28 | 2012-03-29 | Sartorius Stedim Biotech Gmbh | Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium |
| SG11201405185PA (en) * | 2012-03-13 | 2014-10-30 | Emd Millipore Corp | Use of centrifugation-aided infection to increase virus titer |
| US9809800B2 (en) | 2012-11-22 | 2017-11-07 | Asahi Kasei Medical Co., Ltd. | Method for producing parvovirus having high infectivity titer |
| EP2958995A4 (en) * | 2013-02-22 | 2016-11-23 | Agency Science Tech & Res | CHROMATOGRAPHIC CLEANING OF VIRUS PREPARATIONS WITH NEGATIVELY LOADED PARTICLES |
| US9632087B2 (en) * | 2013-09-10 | 2017-04-25 | MockV Solutions | Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles |
| EP3372677B8 (en) * | 2015-11-06 | 2019-09-25 | Asahi Kasei Medical Co., Ltd. | Method for producing parvovirus having high infectivity titer and high purity |
| DE102016005049B4 (de) | 2016-04-26 | 2020-06-18 | Sartorius Stedim Biotech Gmbh | Verfahren zur Bestimmung des logarithmischen Reduktionswertes LRV eines Größenausschlussfilters |
| EP3299454A1 (en) * | 2016-09-21 | 2018-03-28 | Deutsches Krebsforschungszentrum | Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium |
| EP3141611A3 (en) * | 2016-10-21 | 2017-05-10 | Bayer Healthcare LLC | Validation of continuous viral clearance |
| US10961512B2 (en) * | 2017-04-17 | 2021-03-30 | Dao-Yao He | Compositions and kits for purification of viral particles from host cells |
| KR102453351B1 (ko) | 2017-07-05 | 2022-10-07 | 에스케이바이오사이언스(주) | 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법 |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| CN108841794B (zh) * | 2018-06-08 | 2021-11-30 | 苏州良辰生物医药科技有限公司 | 一种病毒原液的制备方法 |
| WO2021261451A1 (ja) * | 2020-06-24 | 2021-12-30 | 旭化成メディカル株式会社 | タンパク質含有溶液の評価方法 |
| US12203914B2 (en) | 2020-11-12 | 2025-01-21 | Sartorius Bioanalytical Instruments, Inc. | Viral clearance evaluation for biological medical product preparation processes |
| JP7612001B2 (ja) | 2021-03-26 | 2025-01-10 | 旭化成メディカル株式会社 | ウイルスクリアランス試験の方法 |
| WO2022252098A1 (zh) * | 2021-05-31 | 2022-12-08 | 中国科学院深圳先进技术研究院 | 噬菌体制剂的制备方法、药物组合物以及应用 |
| WO2026055296A2 (en) * | 2024-09-06 | 2026-03-12 | Amgen Inc. | Production of viral stocks |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02500166A (ja) * | 1987-07-27 | 1990-01-25 | アイジーン、バイオテクノロジー、インコーポレイテッド | ストレプトコッカス感染診断のためのファージ関連リシンの製造 |
| JP2003523169A (ja) * | 1998-12-31 | 2003-08-05 | アバンテイス・フアルマ・エス・アー | ウイルス粒子の分離法 |
| WO2006042414A1 (en) * | 2004-10-22 | 2006-04-27 | Oncolytics Biotech Inc. | Improved viral purification methods |
| JP2006514538A (ja) * | 2002-07-10 | 2006-05-11 | トランスジーン ソシエテ アノニム | 細胞受容体への結合が除去された改変アデノウイルス繊維 |
| WO2008113011A2 (en) * | 2007-03-14 | 2008-09-18 | Ligocyte Pharmaceuticals, Inc. | Virus like particle purification |
| WO2009100521A1 (en) * | 2008-02-12 | 2009-08-20 | Sanofi Pasteur Limited | Methods using ion exchange and gel filtration chromatography for poxvirus purification |
| JP2009535030A (ja) * | 2006-04-28 | 2009-10-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ａａｖの規模適応性の製造方法 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622663A (en) | 1968-06-13 | 1971-11-23 | American Home Prod | Purification of viruses on treated calcium dihydrogen orthophosphate monohydrate adsorbent |
| US3919044A (en) | 1973-03-28 | 1975-11-11 | Armour Pharma | Processes for concentrating and purifying viruses and viral antigens |
| SU579309A1 (ru) | 1973-11-16 | 1977-11-05 | Ленинградский Политехнический Институт Им.М.И.Калинина | Способ получени вакцины |
| FR2475572A1 (fr) | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
| JPS6147185A (ja) | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスの精製方法 |
| JPS6147186A (ja) | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | インフルエンザウイルスの精製方法 |
| JPS6147187A (ja) | 1984-08-10 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 狂犬病ウイルスの精製方法 |
| US7115363B1 (en) | 1986-01-22 | 2006-10-03 | Institut Pasteur | Retrovirus capable of causing AIDS, means and methods for detecting it in vitro |
| US5824482A (en) | 1986-06-23 | 1998-10-20 | Institut Pasteur | Purification, cloning, and characterization of a novel human immunodeficiency virus LAVMAL |
| US4814268A (en) | 1986-10-06 | 1989-03-21 | Kreider John W | Methods for propagating fastidious human viruses and for producing purified suspensions thereof |
| NZ225583A (en) | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
| US5268292A (en) | 1988-06-27 | 1993-12-07 | Robertson Betty H | Reproducible generation of high yields of hepatitis A virus by cell culture |
| GB8914968D0 (en) | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
| US5719051A (en) | 1989-12-22 | 1998-02-17 | Immuno Aktiengesellschaft | Perfusion system and a method for the large scale production of virus or virus antigen |
| DE4003543A1 (de) | 1990-02-06 | 1991-08-08 | Orpegen Med Molekularbioforsch | Verfahren zur abreicherung von viren in loesungen und zur bestimmung der abreicherungsrate von viren |
| US6709811B1 (en) | 1990-05-24 | 2004-03-23 | The United States Of America As Represented By The Department Of Health And Human Services | Versatile reagent for detecting murine leukemia viruses |
| DK0494317T4 (da) | 1990-06-15 | 2001-04-02 | Innogenetics Nv | SIV cpz-ant-retrovirus og anvendelse deraf |
| IT1248075B (it) | 1991-06-18 | 1995-01-05 | Sclavo Spa | Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. |
| FR2686097B1 (fr) | 1992-01-14 | 1994-12-30 | Rhone Merieux | Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie. |
| US5658779A (en) | 1992-03-20 | 1997-08-19 | Ligochem, Inc. | Method of adsorbing viruses from fluid compositions |
| US5602023A (en) | 1992-03-24 | 1997-02-11 | Csatary; Laszlo K. | Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same |
| ATE174382T1 (de) | 1992-10-06 | 1998-12-15 | Dade Behring Marburg Gmbh | Retrovirus aus der hiv-gruppe und dessen verwendung |
| DE69515028T2 (de) | 1994-03-22 | 2000-06-29 | The Immune Response Corp., Carlsbad | Die hocheffiziente herstellung und isolierung von viruspartikeln |
| FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
| DE69534166T2 (de) | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
| US5756341A (en) | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| US5840565A (en) | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
| WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| KR100461701B1 (ko) | 1996-02-29 | 2005-04-06 | 다카라 바이오 가부시키가이샤 | 바이러스의정제및제거방법 |
| KR20000005120A (ko) | 1996-03-29 | 2000-01-25 | 스칸드레트 존 디 | 파라폭스바이러스 벡터 |
| IL127692A0 (en) | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
| WO1998022588A2 (en) * | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| FR2756297B1 (fr) | 1996-11-22 | 1999-01-08 | Centre Nat Rech Scient | Procede de production de virus recombinants |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| US6544769B1 (en) | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| ZA982950B (en) | 1997-04-08 | 1998-10-19 | Merck & Co Inc | Stabilized human papillomavirus formulations |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6410300B1 (en) | 1998-01-12 | 2002-06-25 | The University Of North Carolina At Chapel Hill | Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV |
| US6037456A (en) | 1998-03-10 | 2000-03-14 | Biosource Technologies, Inc. | Process for isolating and purifying viruses, soluble proteins and peptides from plant sources |
| US5994134A (en) | 1998-05-04 | 1999-11-30 | Canji, Inc. | Viral production process |
| US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
| HUP0103091A3 (en) | 1998-08-14 | 2002-03-28 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| AU5689699A (en) | 1998-08-24 | 2000-03-14 | Uab Research Foundation | Methods of producing high titer recombinant adeno-associated virus |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| CN1087032C (zh) | 1998-12-14 | 2002-07-03 | 彭朝晖 | 一种生产重组腺病毒的方法 |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| US6387368B1 (en) | 1999-02-08 | 2002-05-14 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
| US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
| US6316185B1 (en) | 1999-09-29 | 2001-11-13 | Mountain View Pharmaceuticals, Inc. | Quantitation of viruses by light scattering |
| WO2001040448A1 (en) | 1999-12-02 | 2001-06-07 | The General Hospital Corporation | Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon |
| JP2003518380A (ja) | 1999-12-29 | 2003-06-10 | ジェンザイム・コーポレイション | 核酸および他の細胞性汚染混入物質からウイルスベクターを分離するための濾過助剤の使用方法 |
| TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| AU2001285263A1 (en) | 2000-08-25 | 2002-03-13 | The General Hospital Corporation | Selective precipitation of viruses |
| DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| US6951752B2 (en) | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
| US7195905B2 (en) | 2001-12-10 | 2007-03-27 | Baxter Healthcare S.A. | Enveloped virus vaccine and method for production |
| US6825027B2 (en) | 2001-12-10 | 2004-11-30 | Baxter Healthcare S.A. | Method of production of purified hepatitis a virus particles and vaccine preparation |
| CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| ATE386824T1 (de) | 2002-03-29 | 2008-03-15 | Merck & Co Inc | Verfahren zur virusproduktion |
| EP1492890A4 (en) | 2002-03-29 | 2006-10-18 | Merck & Co Inc | EXPLOSIVE PROCEDURE FOR THE PRODUCTION OF ADENOVIRUS AND ADENOVIRUS STEM MIXTURES |
| DE60327069D1 (de) | 2002-04-30 | 2009-05-20 | Oncolytics Biotech Inc | Verbesserte reinigungsmethode für viren |
| ATE360683T1 (de) | 2002-05-14 | 2007-05-15 | Merck & Co Inc | Verfahren zur reinigung von adenovirus |
| US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
| JP2006507800A (ja) | 2002-06-07 | 2006-03-09 | ラージ・スケール・バイオロジー・コーポレイション | 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム |
| WO2004000220A2 (en) | 2002-06-21 | 2003-12-31 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
| ES2305514T5 (es) | 2002-09-05 | 2019-06-14 | Bavarian Nordic As | Método para la amplificación de un poxvirus en condiciones exentas de suero |
| US20050009168A1 (en) | 2003-05-12 | 2005-01-13 | Robbins Joan Marie | Methods and apparatus for Adeno associated virus purification |
| EP1633321A4 (en) | 2003-06-18 | 2006-11-02 | Onyx Pharma Inc | METHOD FOR CLEANING VIRUS |
| AU2003272868A1 (en) | 2003-10-15 | 2005-04-27 | Agtc Gene Technology Company Ltd. | Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors |
| EP1697505A1 (en) | 2003-12-23 | 2006-09-06 | Schering Corporation | Methods for producing a549 cell lines stable in serum-free medium suspension culture |
| US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
| JP2007537760A (ja) | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
| BRPI0511764B8 (pt) | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| DE102004049290A1 (de) | 2004-10-09 | 2006-04-20 | Bayer Healthcare Ag | Verfahren zur Herstellung von Virusmaterial |
| AU2005305347A1 (en) | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying of adenoviral vectors |
| US20060281075A1 (en) | 2004-12-22 | 2006-12-14 | Large Scale Biology Corporation | Purification of viruses, proteins and nucleic acids |
| US7344839B2 (en) | 2004-12-23 | 2008-03-18 | Aurx, Inc. | Virus preparations and methods |
| CA2602944C (en) | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| DE102005047301B4 (de) | 2005-09-30 | 2009-04-16 | Sartorius Stedim Biotech Gmbh | Verfahren zum Nachweis der Virenabreicherung für die Validierung von Filtern und Filtrationsprozessen |
| US20070172846A1 (en) | 2005-11-12 | 2007-07-26 | Introgen Therapeutics, Inc. | Methods for the Production and Purification of Adenoviral Vectors |
| US7754421B2 (en) | 2005-11-18 | 2010-07-13 | National Research Council Of Canada | Detection of intact recombinant viruses |
| KR101157176B1 (ko) | 2005-12-20 | 2012-06-20 | 삼성전자주식회사 | 세포 또는 바이러스의 농축 또는 정제용 미세유동장치 및방법 |
| US7851196B2 (en) | 2006-05-01 | 2010-12-14 | The Regents Of The University Of California | Methods for purifying adeno-associated virus particles |
| CN101516395B (zh) * | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
| JP2010512748A (ja) | 2006-12-15 | 2010-04-30 | シェーリング−プラウ・リミテッド | インフルエンザウイルスを培養物中で複製するための方法 |
| US20080299545A1 (en) * | 2007-03-06 | 2008-12-04 | Shuyuan Zhang | Chromatographic methods for assessing adenovirus purity |
| EP2134757A2 (en) | 2007-03-27 | 2009-12-23 | University of Maryland, College Park | Imprinted polymeric materials for binding various targets such as viruses |
| CN104694489A (zh) | 2007-05-04 | 2015-06-10 | 巴克斯特国际公司 | 用于病毒纯化用连续超速离心的糖溶液配方 |
| BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
| US9651469B1 (en) * | 2016-01-27 | 2017-05-16 | General Electric Company | Electrostatic particle sensor |
-
2011
- 2011-04-08 BR BR112012026095A patent/BR112012026095A2/pt not_active IP Right Cessation
- 2011-04-08 US US13/082,828 patent/US9644187B2/en not_active Expired - Fee Related
- 2011-04-08 JP JP2013504963A patent/JP2013523175A/ja active Pending
- 2011-04-08 CN CN201180018931.9A patent/CN102985536B/zh not_active Expired - Fee Related
- 2011-04-08 SG SG2012075875A patent/SG184833A1/en unknown
- 2011-04-08 KR KR1020127029690A patent/KR101549296B1/ko not_active Expired - Fee Related
- 2011-04-08 WO PCT/US2011/031747 patent/WO2011130119A2/en not_active Ceased
- 2011-04-14 EP EP11162488.8A patent/EP2377927B1/en not_active Revoked
- 2011-04-14 ES ES11162488T patent/ES2736166T3/es active Active
-
2015
- 2015-04-10 JP JP2015081173A patent/JP6284500B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-07 JP JP2017134066A patent/JP6522054B2/ja not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02500166A (ja) * | 1987-07-27 | 1990-01-25 | アイジーン、バイオテクノロジー、インコーポレイテッド | ストレプトコッカス感染診断のためのファージ関連リシンの製造 |
| JP2003523169A (ja) * | 1998-12-31 | 2003-08-05 | アバンテイス・フアルマ・エス・アー | ウイルス粒子の分離法 |
| JP2006514538A (ja) * | 2002-07-10 | 2006-05-11 | トランスジーン ソシエテ アノニム | 細胞受容体への結合が除去された改変アデノウイルス繊維 |
| WO2006042414A1 (en) * | 2004-10-22 | 2006-04-27 | Oncolytics Biotech Inc. | Improved viral purification methods |
| JP2009535030A (ja) * | 2006-04-28 | 2009-10-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ａａｖの規模適応性の製造方法 |
| WO2008113011A2 (en) * | 2007-03-14 | 2008-09-18 | Ligocyte Pharmaceuticals, Inc. | Virus like particle purification |
| WO2009100521A1 (en) * | 2008-02-12 | 2009-08-20 | Sanofi Pasteur Limited | Methods using ion exchange and gel filtration chromatography for poxvirus purification |
Non-Patent Citations (3)
| Title |
|---|
| JPN6014024066; ＣＡＢＡＴＩＮＧＡＮ，Ｍ．: 'Ｉｍｐａｃｔ ｏｆ Ｖｉｒｕｓ Ｓｔｏｃｋ Ｑｕａｌｉｔｙ ｏｎ Ｖｉｒｕｓ Ｆｉｌｔｅｒ Ｖａｌｉｄａｔｉｏｎ．' Ｂｉｏｐｒｏｃｅｓｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｖｏｌ．３， Ｎｏ．１０（Ｓｕｐ）, 200511, ｐｐ． ４０-４ * |
| JPN6014024067; Ｏ'ＮＥＩＬ．Ｐ．Ｆ ＡＮＤ ＢＡＬＫＯＶＩＣ，Ｅ．Ｓ．: 'Ｖｉｒｕｓ ｈａｒｖｅｓｔｉｎｇ ａｎｄ ａｆｆｉｎｉｔｙ-ｂａｓｅｄ ｌｉｑｕｉｄ ｃｈｒｏｍａｔｏｇｒａｐｈｙ． Ａ ｍｅｔｈｏｄ ｆｏｒ ｖｉｒｕｓ ｃｏｎｃｅｎｔｒａｔｉｏｎ ａｎｄ ｐｕｒｉ' Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｖｏｌ．１１， Ｎｏ．２, 199302, ｐｐ．１７３-８ * |
| JPN6014024068; ＡＳＨＥＲ，Ｄ．Ｒ． ｅｔ ａｌ．: 'Ｐｒｅｄｉｃｔｉｎｇ Ｖｉｒｕｓ Ｆｉｌｔｒａｔｉｏｎ Ｐｅｒｆｏｒｍａｎｃｅ ｗｉｔｈ Ｖｉｒｕｓ Ｓｐｉｋｅ Ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ．' Ｂｉｏｐｒｏｃｅｓｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｖｏｌ．９， Ｎｏ．３, 20110301, ｐｐ．２６-３６ * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021114907A (ja) * | 2020-01-22 | 2021-08-10 | 旭化成メディカル株式会社 | パルボウイルスの生産方法 |
| JP7588466B2 (ja) | 2020-01-22 | 2024-11-22 | 旭化成メディカル株式会社 | パルボウイルスの生産方法 |
| WO2021172573A1 (ja) * | 2020-02-28 | 2021-09-02 | 旭化成メディカル株式会社 | ウイルスクリアランス性能の評価方法 |
| JPWO2021172573A1 (https=) * | 2020-02-28 | 2021-09-02 | ||
| JP7390466B2 (ja) | 2020-02-28 | 2023-12-01 | 旭化成メディカル株式会社 | ウイルスクリアランス性能の評価方法 |
| JP2023544512A (ja) * | 2020-09-21 | 2023-10-24 | バイエル・ヘルスケア・エルエルシー | 病原体クリアランスシステムおよび方法 |
| JP7756155B2 (ja) | 2020-09-21 | 2025-10-17 | バイエル・ヘルスケア・エルエルシー | 病原体クリアランスシステムおよび方法 |
| WO2022270105A1 (ja) * | 2021-06-24 | 2022-12-29 | 株式会社島津製作所 | ウイルス試料の濃縮方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US9644187B2 (en) | 2017-05-09 |
| WO2011130119A3 (en) | 2012-03-29 |
| JP2017195897A (ja) | 2017-11-02 |
| EP2377927B1 (en) | 2019-05-22 |
| JP6284500B2 (ja) | 2018-02-28 |
| KR20130020954A (ko) | 2013-03-04 |
| ES2736166T3 (es) | 2019-12-26 |
| KR101549296B1 (ko) | 2015-09-01 |
| JP2015126757A (ja) | 2015-07-09 |
| WO2011130119A8 (en) | 2011-12-29 |
| CN102985536A (zh) | 2013-03-20 |
| JP6522054B2 (ja) | 2019-05-29 |
| SG184833A1 (en) | 2012-11-29 |
| EP2377927A1 (en) | 2011-10-19 |
| US20120088228A1 (en) | 2012-04-12 |
| CN102985536B (zh) | 2017-12-05 |
| WO2011130119A2 (en) | 2011-10-20 |
| BR112012026095A2 (pt) | 2015-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6284500B2 (ja) | 高力価、高純度のウイルスストックの作製方法及びその使用方法 | |
| JP6788056B2 (ja) | 組換えａａｖベクターの改良された精製方法 | |
| JP5898261B2 (ja) | ポックス・ウイルスの精製方法 | |
| US7625570B1 (en) | Methods for purifying adeno-associated virus | |
| JPWO2012176876A1 (ja) | 蛋白製剤の製造方法 | |
| EA034503B1 (ru) | Способ выделения полиовируса из культур клеток | |
| CN108085301A (zh) | 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒 | |
| EP3121268B1 (en) | Methods for purification of a virus produced in vitro and clearance assay for the virus | |
| JP7390466B2 (ja) | ウイルスクリアランス性能の評価方法 | |
| Luong et al. | Rapid bench to bedside therapeutic bacteriophage production | |
| JP6908331B2 (ja) | ポリジアリルジアルキルアンモニウム塩を使用したアデノ随伴ウイルスを単離する方法 | |
| Shoaebargh et al. | Developing and Optimizing Monolithic Column Chromatography Purification Process for Oncolytic Rhabdoviral Vectors | |
| JP7588466B2 (ja) | パルボウイルスの生産方法 | |
| JP2025167597A (ja) | ウイルスクリアランス性能の決定方法 | |
| Heldt | Affinity adsorption of viruses using small peptide ligands | |
| HK40000235B (en) | Methods for isolating adeno-associated virus using a polydiallyldialkylammonium salt | |
| HK1231118B (en) | Methods for purification of a virus produced in vitro and clearance assay for the virus | |
| HK40000235A (en) | Methods for isolating adeno-associated virus using a polydiallyldialkylammonium salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140610 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140910 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140918 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141010 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150410 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150413 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150512 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150710 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160627 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161011 |